Dr. Kuruvilla was a PhD student in Materials Science and Engineering mentored by Dr. Greve. He worked on the development of a nanoparticle-based drug delivery system to improve hepatic cancer therapy, drawing upon novel chemistry, preclinical mouse models, and MR imaging to assess the merits of his work. Dr. Kuruvilla is now studying the ability for nanotechnology to improve immunotherapeutic strategies as a Postdoctoral Research Fellow at Stanford University.
Nanoparticle design for targeted, enzyme-activated drug delivery to hepatic cancer tissue.
- S. P. Kuruvilla, G. Tiruchinapally, M. ElSayed. “Effect of N-acetylgalactosamine ligand valency on targeting dendrimers to hepatic cancer cells.” Submitted.
S. P. Kuruvilla, G. Tiruchinapally, A. C. Crouch, M. ElSayed, J. M. Greve. “Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model.” PLoS ONE 2017, 12 (8), e0181944.
S. P. Kuruvilla, G. Tiruchinapally, M. ElAzzouny, M. ElSayed. “N-Acetylgalactosamine-targete
d delivery of dendrimer-doxorubicin conjugates influences doxorubicin cytotoxicity and metabolic profile in hepatic cancer cells.” Adv. Healthcare Mater. 2017, 6, 1601046.
S. H. Medina, G. Tiruchinapally, M.V. Chevliakov, Y.Y. Durmaz, S.P. Kuruvilla, M. ElSayed. “Enzyme-activated nanoconjugates for tunable release of doxorubicin in hepatic cancer cells.” Biomaterials 2013, 34, 4655-4666.